Long-Term Effects of Teplizumab in Real-World Care
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study follows people who have already received teplizumab (a treatment to delay type 1 diabetes) to see how they do over time. It aims to understand the long-term effects in routine care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have received at least one teplizumab infusion within the last 6 weeks.
- When you got your first teplizumab infusion, your doctor said you had Stage 2 type 1 diabetes (this means early-stage, before insulin is needed).
- You or your legal guardian agree to take part by signing a consent form.
- You have not taken part in a teplizumab clinical trial before.
- You have not been in any other clinical trial in the last 6 months (observational studies are okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at real-world outcomes in patients with type 1 diabetes who received teplizumab through managed access programs. It helps researchers understand how well the treatment works outside of a clinical trial setting.
This study watches people with stage 2 type 1 diabetes who either get teplizumab or not, to compare their real-world experiences. It helps researchers learn how the drug affects daily life.
This study tracks people with stage 2 type 1 diabetes to see how they do over time, either with or without treatment with a drug called TZIELD. It helps doctors learn more about the disease and the effects of this treatment.
This study tests two different medications (Anti-Thymocyte Globulin and Adalimumab or Verapamil) to see if they can slow down the loss of insulin production in people with newly diagnosed type 1 diabetes. Participants will be randomly assigned to receive one of the treatments and will be followed for about a year to see how well their bodies still make insulin.
This Phase 1/2 study tests whether CELZ-201 is safe and can help the body keep making some of its own insulin in people who were recently diagnosed with type 1 diabetes. You may be eligible if your diabetes started within the past year and your tests show you still have some insulin-making activity.
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.